Table 2. Risk factors for PKDL development in past treated VL patients, exact logistic regression.
| Factors | Past VL (no.) | PKDL | Unadjusted ORα | 95% CIβ | Adjusted OR | 95% CI |
| no. (%) | ||||||
| Age (year) median (IQR)δ | 680 | 28 (15;40) | ||||
| ≤14 year | 167 | 3 (1.8) | referent | |||
| 15–29 year | 194 | 6 (3.1) | 1.74 | 0.37–10.93 | ||
| 30–44 year | 189 | 4 (2.1) | 1.18 | 0.20–8.18 | ||
| ≥45 year | 130 | 3 (2.3) | 1.29 | 0.17–9.80 | ||
| Gender | ||||||
| Male | 370 | 8 (2.2) | referent | |||
| Female | 310 | 8 (2.6) | 1.20 | 0.39–3.71 | ||
| Drug used for VL treatment | ||||||
| Adequate SSGσ treatment | 543 | 11 (2.0) | referent | referent | ||
| Inadequate SSG treatment (≤20 injection) | 17 | 5 (29.4) | 19.77 | 4.66–75.00 | 11.68 | 2.71–45.47 |
| Other treatment (Miltefosine & Amphotericin B) | 120 | 0 (0.0) | 0.29* | 0.00–1.80 | 0.67* | 0.00–4.59 |
| Supervised treatment with SSG at BPKIHS | ||||||
| Adequate treatment | 247 | 1 (0.4) | ||||
| Inadequate treatment (≤20 injection) | 0 | 0 (0.0) | ||||
| Unsupervised treatment with SSG at other places (Govt. & pvt) | ||||||
| Adequate treatment | 296 | 10 (3.4) | ||||
| Inadequate treatment (≤20 injection) | 17 | 5 (29.4) | ||||
| Hospitalization during treatment with SSG | ||||||
| No | 334 | 12 (3.6) | referent | |||
| Yes | 226 | 4 (1.8) | 0.45 | 0.14–1.40 |
α: OR : odds ratio;
β: CI: confidence interval;
δ: IQR: Inter quartile range;
σ: SSG : Sodium stibogluconate.
*: Median unbiased estimates (MUE).